ViCentra, a European medical device company redefining insulin delivery for people with diabetes, today announced the successful close of an upsized $85 million Series D financing.

The round was led by new investor Innovation Industries, a leading European deeptech venture capital firm. The round included matching participation from existing investors Partners in Equity and Invest-NL, alongside continued support from EQT Life Sciences and Health Innovations.

The funding will accelerate manufacturing scale-up, enable the launch of the next-generation Kaleido 2 patch pump in Europe, and support preparations for U.S. market entry.

Kaleido is the smallest, lightest, and most precise insulin patch pump in its class, uniquely designed as a lifestyle product that is discreet, intuitive, and personalized. Designed to feel more like personal technology than a traditional medical device, Kaleido features premium materials and allows users to select their preferred aluminum shell from ten preset color options.

Integrated with Diabeloop’s self-learning automated insulin delivery algorithm and compatible with the Dexcom CGM sensor, Kaleido positions ViCentra at the forefront of next-generation diabetes care, helping more users improve their quality of life. Strong initial commercial uptake in Germany, France, and the Netherlands has driven demand beyond expectations, and this financing enables ViCentra to scale quickly to meet it.

“Kaleido is a true disruptor — small, discreet, featherlight, and beautifully designed. It empowers people with diabetes by offering a more personal and distinctive choice in both function and style. Built with empathy and precision, it honors those who live with diabetes every day. With this funding, we can now meet surging European demand and fast-track our entry into the US market. This is a pivotal moment — for ViCentra, and for the community we serve,” said Tom Arnold, CEO at ViCentra.

The global insulin delivery market is one of the largest and fastest-growing medical device segments, driven by rising diabetes prevalence and increasing demand for solutions that blend clinical effectiveness with everyday usability. The insulin pump market alone is projected to reach over $14 billion by 2034. Patch pumps represent the fastest-growing segment, reflecting a broader industry shift toward compact, wearable, and patient-centric solutions. ViCentra is uniquely positioned to meet this need, offering a user-friendly, design-led alternative to traditional insulin delivery systems.

“ViCentra is redefining insulin pump therapy with a platform that truly centers the user experience — combining clinical performance with design simplicity and wearability,” said Caaj Greebe, partner at Innovation Industries. “At Innovation Industries, we invest in pioneering companies that blend world-class technology with clear commercial potential. ViCentra exemplifies this by delivering a next-generation system addressing the urgent need for better treatment options in diabetes care. We’re proud to lead this investment round and partner with Tom and the team as they deepen and expand their presence in Europe and prepare for U.S. entry.”

ViCentra will attend the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), September 15–19, 2025, at the Vienna Congress & Convention Center (VIECON) in Vienna, Austria, to meet with clinicians, investors, and strategic partners and discuss advancements in insulin delivery.